Equities

OmniAb Inc

OABI:NMQ

OmniAb Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.58
  • Today's Change-0.150 / -3.17%
  • Shares traded191.03k
  • 1 Year change-9.66%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 15:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8788--
Total Receivables, Net3.843021
Total Inventory------
Prepaid expenses------
Other current assets, total4.076.401.41
Total current assets9512523
Property, plant & equipment, net384120
Goodwill, net848484
Intangibles, net155167176
Long term investments------
Note receivable - long term------
Other long term assets2.193.581.50
Total assets375421304
LIABILITIES
Accounts payable4.412.972.92
Accrued expenses9.307.284.26
Notes payable/short-term debt000
Current portion long-term debt/capital leases----0.00
Other current liabilities, total9.401613
Total current liabilities232621
Total long term debt000
Total debt000.00
Deferred income tax112122
Minority interest------
Other liabilities, total263228
Total liabilities618070
SHAREHOLDERS EQUITY
Common stock0.010.01--
Additional paid-in capital354330--
Retained earnings (accumulated deficit)(39)11234
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.050.01--
Total equity315341234
Total liabilities & shareholders' equity375421304
Total common shares outstanding117115115
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.